Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus
Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus
复制标题
DOI：
10.1086/652655
复制
发表时间：
2010-06-01
影响因子：
11.8
通讯作者：
Chappell, James D.
中科院分区：
文献类型：
--
作者：
Dulek, Daniel E.;Williams, John V.;Chappell, James D.
接受奥司他韦治疗2009年新型H1N1甲型流感感染的免疫抑制患者可能会产生耐药性，导致治疗失败。在同情使用的基础上，静脉注射扎那米韦用于严重免疫抑制的患有严重奥司他韦耐药的新型H1N1肺炎的儿科患者。该方案耐受性良好，并与病毒负荷降低相关。
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.